Trade REPL stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Replimune Group, Inc. (REPL) is trading at US$20.88, up 4.30% today as of Nov 6, 12:36 EST. The company has a market capitalisation of US$1.39B. Over the past 52 weeks, REPL has traded between US$1.50 and US$21.26. On Syfe you can trade REPL with $0 commission and add it to your watchlist.
| Previous close | US$20.02 |
|---|---|
| Market cap | US$1.39B |
| 52-week range | US$1.50 – US$21.26 |
| Volume | 4M |
| Exchange | US |
Replimune Group, Inc.
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
Year: 2018
Replimune Receives Approval to Launch Tudriqev in the US for Melanoma
Oct 1, 8:33 PM · MT Newswires
Replimune Fiscal Q1 Net Loss Narrows
Aug 14, 12:26 PM · MT Newswires
--Earnings Flash (REPL) Replimune Posts Fiscal Q1 Net Loss $0.72 a Share, vs. FactSet Est of $0.66 Loss
Aug 14, 12:09 PM · MT Newswires
Replimune Group, Inc. (REPL) stock is trading at US$20.88, +4.30% from the previous close of US$20.02.
The market cap for Replimune Group, Inc. (REPL) stock is approximately US$1.39B.
The 52-week high for Replimune Group, Inc. (REPL) stock is US$21.26.
The 52-week low for Replimune Group, Inc. (REPL) stock is US$1.50.
Replimune Group, Inc. (REPL) does not currently pay a dividend.
Stay on top of REPL
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
